GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » Cash Flow from Financing

Medtronic (Medtronic) Cash Flow from Financing

: $-6,981 Mil (TTM As of Jan. 2024)
View and export this data going back to 1980. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jan. 2024, Medtronic paid $75 Mil more to buy back shares than it received from issuing new shares. It spent $311 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $917 Mil paying cash dividends to shareholders. It spent $197 Mil on other financial activities. In all, Medtronic spent $1,500 Mil on financial activities for the three months ended in Jan. 2024.


Medtronic Cash Flow from Financing Historical Data

The historical data trend for Medtronic's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medtronic Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,431.00 -4,198.00 -4,136.00 -5,336.00 -4,960.00

Medtronic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,134.00 -4,890.00 -501.00 -90.00 -1,500.00

Medtronic Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Medtronic's Cash from Financing for the fiscal year that ended in Apr. 2023 is calculated as:

Medtronic's Cash from Financing for the quarter that ended in Jan. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6,981 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medtronic  (NYSE:MDT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Medtronic's issuance of stock for the three months ended in Jan. 2024 was $57 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Medtronic's repurchase of stock for the three months ended in Jan. 2024 was $-132 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Medtronic's net issuance of debt for the three months ended in Jan. 2024 was $-311 Mil. Medtronic spent $311 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Medtronic's net issuance of preferred for the three months ended in Jan. 2024 was $0 Mil. Medtronic paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Medtronic's cash flow for dividends for the three months ended in Jan. 2024 was $-917 Mil. Medtronic spent $917 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Medtronic's other financing for the three months ended in Jan. 2024 was $-197 Mil. Medtronic spent $197 Mil on other financial activities.


Medtronic Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Medtronic's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Medtronic (Medtronic) Business Description

Address
Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Executives
Brett A. Wall officer: EVP & Group Pres Restora Thera 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith officer: EVP Global Ops & Supply Chain 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro officer: EVP & President, Surgical OU 710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten officer: EVP & President EMEAC 710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis director C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon officer: EVP & Group President Diabetes MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca director 358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill officer: EVP & Chief Financial Officer 1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong officer: EVP GENERAL COUNSEL & SECR 3M CENTER, ST. PAUL MN 55144-1000
Robert John White officer: EVP & President MITG MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman officer: SVP General Counsel & Corp Sec MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha officer: Sr VP, Strategy & Bus Dev 710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk officer: Chief Accounting Officer 5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat officer: EVP & President of Americas MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432

Medtronic (Medtronic) Headlines